This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.This maker of drug delivery technologies is expected to post quarterly earnings of $0.55 per share in its upcoming report, which represents a year-over-year change of -47.1%. NASDAQ data is at least 15 minutes delayed. NYSE and AMEX data is at least 20 minutes delayed. Real time prices by BATS. Delayed quotes by FIS. Visit to get our data and content for your mobile app or website. Visit Performance Disclosure for information about the performance numbers displayed above. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The monthly returns are then compounded to arrive at the annual return. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. These returns cover a period from Januthrough April 3, 2023. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. and Morningstar, Inc.Ĭopyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. FibroGen currently boasts a Zacks Rank of #3 (Hold). Compared to the company's year-ago EPS, this represents a change of -11.8%. FGEN has returned -13.2% in the past month.įibroGen's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.76. FibroGen ( FGEN Quick Quote FGEN - Free Report), another stock in the same industry, closed the last trading session 2.4% lower at $16.11. is part of the Zacks Medical - Drugs industry. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here > The stock currently carries a Zacks Rank #2 (Buy). So, make sure to keep an eye on PRPH going forward to see if this recent jump can turn into more strength down the road. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. Revenues are expected to be $16.3 million, down 65.7% from the year-ago quarter.Įarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.įor ProPhase Labs, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of -113.2%. ProPhase Labs has five subsidiaries under its belt, conducting business in five distinct markets, genome sequencing, diagnostics, biopharmaceuticals, healthcare product development and supplements. The sudden soaring of the stock prices can be attributed to the positive momentum built around the performance of ProPhase's wholly-owned subsidiary companies. This compares to the stock's 1.3% loss over the past four weeks. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. ( PRPH Quick Quote PRPH - Free Report) shares ended the last trading session 8.5% higher at $8.42.
0 Comments
Leave a Reply. |